Technology

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing hidden access barriers, streamlining treatment pathways, and challenging outdated utilization management practices.

Capan discusses the collaboration between AWS and EVERSANA in the first part of this two-part interview.

Sheeran continues the conversation on the collaboration between AWS and EVERSANA in the second part of this interview.

AI is transforming content reviews to focus on relevant use, not just generation.

Ted Sweetser discusses turning information into usable datasets and pulling insights from them.

Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.

Ted Sweetser discusses how the technology is providing greater insight into how marketing materials are being viewed.

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Ted Sweetser discusses how the technology is expanding the amount of content that can be created.

Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.

The Verseon CEO discusses how this advanced technology is helping to discover new drug candidates.

Davidi Vortman, CEO, UltraSight, discusses how AI-powered heart scan technology can help high-risk cardiovascular disease patients.

As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.

Hyfe’s CEO discusses the importance of DTx and how it can change the way certain conditions are treated.

Marcel Botha, CEO of 10XBeta, identifies the most significant technological innovations in medical device manufacturing that will be crucial for future pandemic preparedness and supply chain stability.

Matthew Yelovich, partner at Cleary Gottlieb, discusses his transition in late-2024 from working as a federal prosecutor to a role at Cleary Gottlieb, as well as how he sees the intersection of technology and law evolving in the Bay Area.

Matthew Yelovich, partner at Cleary Gottlieb, discusses some of the broader implications for corporate governance and accountability the Theranos case highlights.

Rahman discusses Google Gemini and what it could mean to the future of pharma commercialization and content development.

If used properly, AI can be a game-changer for drug development.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Jennifer Kyle, CEO and founder of Condor, explores how improving financial management directly impacts drug pricing.

Jennifer Kyle, CEO and founder of Condor, discusses the inspiration behind creating a financial cloud platform specifically for biopharma R&D.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses ethical considerations surrounding AI use in medication access and how the industry can ensure that these technologies are used responsibly and equitably.